To compare overall survival (OS) in patients with inoperable, early stage non-small cell lung cancer (NSCLC) randomized to stereotactic body radiation therapy (SBRT) with or without atezolizumab.
Patients must have histologically or cytologically proven Stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC) without radiographic evidence of nodal or distant involvement (N0M0). Patients may have T3 disease with the exclusion of multifocal tumors and pericardial involvement.
21st Century Oncology will be moving to their new home as part of the global GenesisCare network. The 21st Century Oncology website will no longer exist after November 2020.
There will be no disruption in your care team, location, or contacts. There will simply be a new website, new look and feel, and patients will benefit from the latest treatment technology and evidence-based cancer care. We look forward to serving you as part of the GenesisCare team.